111 related articles for article (PubMed ID: 10367809)
21. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
Gellad ZF; Reed SD; Muir AJ
Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
[TBL] [Abstract][Full Text] [Related]
22. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
23. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
Haj-Ali Saflo O; Hernández Guijo JM
Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
[TBL] [Abstract][Full Text] [Related]
24. Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report.
Tice JA; Chahal HS; Ollendorf DA
JAMA Intern Med; 2015 Sep; 175(9):1559-60. PubMed ID: 26167717
[No Abstract] [Full Text] [Related]
25. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Einecke D
MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
[No Abstract] [Full Text] [Related]
26. Special report: cost-effectiveness studies of new hepatitis C treatments.
Mark DH;
Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
[No Abstract] [Full Text] [Related]
27. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
[TBL] [Abstract][Full Text] [Related]
28. It's time to end insurance restrictions on life-saving hepatitis C treatments.
Clary R
Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
[No Abstract] [Full Text] [Related]
29. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
Bickerstaff C
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):787-800. PubMed ID: 26289734
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
Koff RS
J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
[No Abstract] [Full Text] [Related]
31. Therapy of hepatitis C: cost-effectiveness analysis.
Koff RS
Hepatology; 1997 Sep; 26(3 Suppl 1):152S-155S. PubMed ID: 9305681
[TBL] [Abstract][Full Text] [Related]
32. Treatment strategy for hepatitis C: a dilemma for the payers and the providers.
Haque M; Zariat A
Am J Gastroenterol; 2014 Dec; 109(12):1953-4. PubMed ID: 25470586
[No Abstract] [Full Text] [Related]
33. Does patient cost sharing for HCV drugs make sense?
Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
[No Abstract] [Full Text] [Related]
34. Hepatitis C therapy: is it really worth it?
Johanson JF
Am J Gastroenterol; 1999 May; 94(5):1412-3. PubMed ID: 10235231
[No Abstract] [Full Text] [Related]
35. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C: current and future therapies.
Mishra P; Jensen DM
Mt Sinai J Med; 2008 Aug; 75(4):405-14. PubMed ID: 18729159
[No Abstract] [Full Text] [Related]
37. Hepatitis C: An Eastern Perspective.
Dan YY; Lim SG
Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
[TBL] [Abstract][Full Text] [Related]
38. [Costs of modern treatment of chronic hepatitis C].
Stiefelhagen P; Sarrazin C
Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
[No Abstract] [Full Text] [Related]
39. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Logge C; Vettorazzi E; Fischer L; Nashan B; Sterneck M
Transpl Int; 2013 May; 26(5):527-34. PubMed ID: 23517333
[TBL] [Abstract][Full Text] [Related]
40. New HCV drugs trigger race for more tolerable therapies.
Williams SC
Nat Med; 2011 Dec; 17(12):1526. PubMed ID: 22146431
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
